Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2018-10-12
|
CMB305 and atezolizumab |
soft tissue sarcoma, locally advanced, relapsed, or metastatic NY-ESO-1+ synovial sarcoma or myxoid/round-cell liposarcoma. |
2 |
Immune Design (USA - MA) |
Cancer - Oncology |
2018-10-12
|
CMB305 (LV305 and G305) - dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 gene05 |
synovial sarcoma |
3 |
Immune Design (USA - MA) |
Cancer - Oncology |
2018-10-11
|
lifileucel - LN-144 |
metastatic melanoma |
2 |
Lion Biotechnologies (USA - CA), now Iovance Biotherapeutics (USA - CA) |
Cancer - Oncology |
2018-10-06
|
LOXO-292 |
RET-fusion non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other tumors with increased RET activity |
1-2 |
Loxo Oncology (USA - CT) |
Cancer - Oncology |
2018-10-06
|
Translarna™ (ataluren) |
Duchenne muscular dystrophy |
observational |
PTC Therapeutics (USA - NJ) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2018-10-06
|
Spinraza® (nusinersen) |
spinal muscular atrophy (SMA) |
2 |
Biogen (USA - MA) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2018-10-05
|
AT132 |
X-Linked Myotubular Myopathy (XLMTM) |
1-2 |
Audentes Therapeutics (USA - CA) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2018-10-05
|
Orbactiv™ (oritavancin) |
infections due to presumed or confirmed gram-positive bacteria |
observational |
Melinta Therapeutics (USA - CT) |
Infectious diseases |
2018-10-04
|
birinapant and pembrozilumab |
treatment-resistant solid tumours |
1-2 |
Medivir (Sweden) |
Cancer - Oncology |
2018-10-03
|
risdiplam - RG7916/RO7034067 |
type 1spinal muscular atrophy (SMA) |
2 |
PTC Therapeutics (USA - NJ) Roche (Switzerland) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2018-10-03
|
AAVrh74.MHCK7.micro-Dystrophin |
Duchenne muscular dystrophy (DMD) |
1-2 |
Sarepta Therapeutics (USA - MA) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2018-10-03
|
Biktarvy® (BIC/FTC/TAF - bictegravir (50 mg) and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF) |
HIV-1 infection in adults |
3 |
Gilead Sciences (USA - CA) |
Infectious diseases |
2018-10-03
|
ALN-AAT02 |
AAT deficiency-associated liver disease (alpha-1 liver disease) |
1-2 |
Alnylam Therapeutics (USA - MA) |
Rare diseases - Genetic diseases - Hepatic diseases - Liver diseases |
2018-10-02
|
Kineret® (anakinra) |
acute gout |
2 |
Swedish Orphan Biovitrum - SOBI (Sweden) |
Inflammatory diseases |
2018-10-01
|
MIV-818 |
advanced liver cancer including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma and liver metastases from solid tumors |
1-2 |
Medivir (Sweden) |
Cancer - Oncology |
2018-09-29
|
IPH4102 |
cutaneous T-cell lymphoma (CTCL) and especially their aggressive forms: Sezary Syndrome and Transformed Mycosis Fungoides |
1 |
Innate Pharma (France) |
Cancer - Oncology - Rare diseases |
2018-09-28
|
ATOR-1017 |
|
preclinical |
Alligator Bioscience (Sweden) |
Cancer - Oncology |
2018-09-27
|
givosiran (ALN-AS1) |
acute hepatic porphyria |
3 |
Alnylam Therapeutics (USA - MA) |
Rare diseases - Metabolic diseases |
2018-09-26
|
CSTD002-NK (adoptive NK cell therapy) |
reduction of relapse in high risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT) |
2 |
Cytosen Therapeutics (USA - TX) |
Cancer - Oncology |
2018-09-25
|
Imfinzi® (durvalumab) (MEDI4736) |
non-small cell lung cancer (NSCLC) |
3 |
AstraZeneca (UK) |
Cancer - Oncology |